---
title: Improve walking endurance and strength
nct_id: NCT06893055
phase: NA
status: RECRUITING
sponsor: General University Hospital, Prague
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06893055"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06893055"
last_fetched: "2026-05-10T14:02:57.516Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking endurance and strength

**Goal (in five words):** Improve walking endurance and strength

**Official Title:** Strength-Endurance Circuit Training in Parkinson's Disease: Effects on Disease Severity, Physical Performance, Blood Biomarkers and Quality of Life.

**Trial ID:** [NCT06893055](https://clinicaltrials.gov/study/NCT06893055)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** General University Hospital, Prague
- **Target Enrollment:** 90 participants
- **Start Date:** 2025-03-03
- **Completion Date:** 2026-12
- **Conditions:** Parkinson Disease, Idiopathic
- **Interventions:** Strength-Endurance Training, Endurance Training
- **Intervention Types:** OTHER

## Summary For Families

Researchers want to know whether a structured strength-endurance circuit program can lessen Parkinson's signs, boost physical performance, shift blood biomarkers linked to brain health, and improve quality of life compared with regular endurance training. The program uses supervised circuits that combine resistance exercises to build muscle strength and endurance with aerobic intervals to raise cardiovascular fitness, a combination meant to improve mobility and daily function and that may increase helpful proteins like BDNF and reduce inflammatory markers, while complementing stable levodopa or other dopaminergic medications rather than replacing them. The trial is looking for adults 18 to 75 with idiopathic Parkinson's at Hoehn and Yahr stage up to 2.5 who can walk without support and are on stable dopaminergic treatment; people with deep brain stimulation, freezing of gait, camptocormia, major limiting health issues, or low expected attendance are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* age ≥18 years
* diagnosis of idiopathic Parkinson´s disease
* Hoehn-Yahr Scale ≤ 2,5
* stable dopaminergic medication

Exclusion Criteria:

* age ≥75 years
* Hoehn-Yahr Scale ≥ 2,5
* deep brain stimulation
* presence of freezing
* Camptocormia
* inability to walk without support
* inability to perform study procedures
* limiting co-morbidities
* attendance at training sessions below 70%
```

## Locations (1)

- Department of Neurology and Centre of Clinical Neuroscience First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Prague, Czechia _(50.0880, 14.4208)_
  - Jakub Vítek, MSc. — (CONTACT) — +420 224 965 513 — jakub.vitek@vfn.cz

## Central Contacts

- Jakub Vítek, MSc. — (CONTACT) — +420 224 965 513 — jakub.vitek@vfn.cz

---

*Canonical: https://parkinsonspathways.com/trial/NCT06893055*  
*HTML version: https://parkinsonspathways.com/trial/NCT06893055*  
*Source data: https://clinicaltrials.gov/study/NCT06893055*